MissionIR today announces that its interview with Dan O’Conner, the president and Chief Executive Officer of Advaxis, is now available online. The audio interview can be heard at http://adxs.missionir.com/interview.html.
In the interview, O’Conner provides crucial details of Advaxis’ technology and lead drug candidate ADXS-HPV, and provides highlights of completed, current and upcoming clinical trials for several indications, including cervical cancer.
Advaxis is operated by a highly experienced management team with numerous years of pharmaceutical development, business and other relative experience. O’Conner describes the backgrounds and qualifications of several key members of Advaxis management, as well as details his own 50 years of executive involvement in the biopharmaceutical industry.
In his comprehensive review of the company, O’Conner also touches on Advaxis’ business outlook for 2013 and its overall business strategy and financial viability.
“We intend to seek an uplisting for national exchange in the near term,” says O’Conner. “We strongly believe that the combination of completing the reverse split of our stock and the contemplated uplisting could heighten the interest of the financial community in Advaxis as well as potentially broaden the pool of investors as they consider investing in the company while strengthening financial health.”
For additional information, please visit: www.ADXS.MissionIR.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment